You are here

Cancer Cell DOI:10.1016/j.ccell.2018.10.014

KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance.

Publication TypeJournal Article
Year of Publication2018
AuthorsHinohara, K, Wu, H-J, Vigneau, S, McDonald, TO, Igarashi, KJ, Yamamoto, KN, Madsen, T, Fassl, A, Egri, SB, Papanastasiou, M, Ding, L, Peluffo, G, Cohen, O, Kales, SC, Lal-Nag, M, Rai, G, Maloney, DJ, Jadhav, A, Simeonov, A, Wagle, N, Brown, M, Meissner, A, Sicinski, P, Jaffe, JD, Jeselsohn, R, Gimelbrant, AA, Michor, F, Polyak, K
JournalCancer Cell
Date Published2018 Nov 14
ISSN1878-3686
Abstract

Members of the KDM5 histone H3 lysine 4 demethylase family are associated with therapeutic resistance, including endocrine resistance in breast cancer, but the underlying mechanism is poorly defined. Here we show that genetic deletion of KDM5A/B or inhibition of KDM5 activity increases sensitivity to anti-estrogens by modulating estrogen receptor (ER) signaling and by decreasing cellular transcriptomic heterogeneity. Higher KDM5B expression levels are associated with higher transcriptomic heterogeneity and poor prognosis in ER breast tumors. Single-cell RNA sequencing, cellular barcoding, and mathematical modeling demonstrate that endocrine resistance is due to selection for pre-existing genetically distinct cells, while KDM5 inhibitor resistance is acquired. Our findings highlight the importance of cellular phenotypic heterogeneity in therapeutic resistance and identify KDM5A/B as key regulators of this process.

DOI10.1016/j.ccell.2018.10.014
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/30472020?dopt=Abstract

Alternate JournalCancer Cell
PubMed ID30472020